Elicera Therapeutics AB

Elicera Therapeutics AB

0.24
EUR
+0.01
(+3.74%)
-0.03EPS
15.95MMarket Cap
Nov 27Next Earn

Total Valuation

EUR

As of June 30, 2026, Elicera Therapeutics AB carries a market capitalization of 15.95M, placing it among publicly traded companies globally. Its enterprise value stands at 10.70M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap15.95M
Enterprise Value10.70M

Important Dates

Elicera Therapeutics AB's next confirmed earnings release is scheduled for November 27, 2026.

Earnings Date11/27/2026

Share Statistics

As of June 30, 2026, Elicera Therapeutics AB has 66.74M shares outstanding.

Shares Outstanding66.74M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio3.14
P/TBV Ratio3.14
P/FCF Ratio-5.21
P/OCF Ratio-5.21

Financial Position

As of June 30, 2026, Elicera Therapeutics AB maintains a current ratio of 17.81, meaning it holds 17.8x the short-term assets needed to cover near-term liabilities.

Current Ratio17.81
Quick Ratio17.37
Interest Coverage-1,861.18

Financial Efficiency

Over the twelve months ended June 30, 2026, Elicera Therapeutics AB posted a negative return on equity (ROE) of -41.69, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -35.79, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 2.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-41.69
Return on Assets (ROA)-35.79
Employee Count2.00

Stock Price Statistics

EUR

As of the close on November 17, 2026, Elicera Therapeutics AB's stock has declined approximately 50.87% over the past 52 weeks. The 50-day moving average sits at 0.25, while the 200-day moving average is 0.31.

52-Week Price Change-50.87%
50-Day Moving Average0.25
200-Day Moving Average0.31

Income Statement

EUR

Over the twelve months ended June 30, 2026, Elicera Therapeutics AB generated - - in revenue and converted that into -1.62M in net income, yielding earnings per share of -0.03. EBITDA reached -1.66M, while operating income came in at -1.66M.

Operating Income-1.66M
Pretax Income-1.62M
Net Income-1.62M
EBITDA-1.66M
EBIT-1.66M
Earnings Per Share (EPS)-0.03

Balance Sheet

EUR

These figures are as of June 30, 2026. Total book value stands at 5.08M, with working capital of 5.08M providing operational flexibility.

Cash & Cash Equivalents5.25M
Net Debt-5.25M
Equity (Book Value)5.08M
Book Value Per Share0.08
Working Capital5.08M

Cash Flow

EUR

Elicera Therapeutics AB produced -2.32M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -2.32M - equivalent to -0.05 per share.

Operating Cash Flow-2.32M
Free Cash Flow-2.32M
FCF Per Share-0.05

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -19.19: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -25.03, meaning Elicera Therapeutics AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-25.03
FCF Yield-19.19

Stock Splits

Elicera Therapeutics AB's most recent stock split took place on May 11, 2026 with a 38:39 split ratio.

Last Split Date5/11/2026
Split Ratio38:39

Scores

As of June 30, 2026, Elicera Therapeutics AB has an Altman Z-Score of 31.52, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score31.52